|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6950 EUR | +14.50% |
|
+10.86% | -52.86% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |
Company Valuation: AB Science
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 332.2 | 180.9 | 57.55 | 112 | 51.85 | - | - |
| Change | - | -45.55% | -68.19% | 94.7% | -53.73% | - | - |
| Enterprise Value (EV) | 332.2 | 180.9 | 57.55 | 112 | 51.85 | 51.85 | 51.85 |
| Change | - | -45.55% | -68.19% | 94.7% | -53.73% | 0% | 0% |
| P/E | -24.4x | -17.8x | -5.88x | - | - | - | - |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0.6x | 0.2x | - | - | - | - |
| Capitalization / Revenue | - | 187x | 53.7x | 95.4x | 43.2x | 39.9x | 32.4x |
| EV / Revenue | - | 0x | 0x | 0x | 43.2x | 39.9x | 32.4x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | -0x | -0x | 0x | -7.98x | -8.1x | - |
| EV / FCF | - | -0x | - | -0x | -8.1x | -14.4x | -13.3x |
| FCF Yield | - | -9.52% | - | -4.08% | -12.3% | -6.94% | -7.52% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.29 | -0.2 | -0.15 | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | 0.97 | 1.072 | 1.174 | 1.2 | 1.3 | 1.6 |
| EBITDA | - | -11.16 | -5.416 | - | - | - | - |
| EBIT 1 | - | -13.43 | -6.083 | 0.639 | -6.5 | -6.4 | - |
| Net income | -13.62 | -10.05 | -7.831 | - | - | - | - |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 7.0900 | 3.5550 | 0.8820 | 1.5360 | 0.6480 | 0.6480 | 0.6480 |
| Nbr of stocks (in thousands) | 46,861 | 50,891 | 65,248 | 72,947 | 80,015 | - | - |
| Announcement Date | 3/1/23 A | 5/15/24 A | 5/13/25 A | 5/13/26 A | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 29.28x | 5.36x | 22.26x | 2.65% | 316B | ||
| 24.88x | 3.38x | 11.92x | 1.6% | 73.28B | ||
| 12.48x | 6.33x | 9.65x | - | 9.87B | ||
| 15.86x | 1.99x | 6.75x | 2.85% | 8.15B | ||
| 21.29x | 6.02x | 17.05x | -.--% | 4.38B | ||
| 36.73x | 2.34x | 27.37x | 0.75% | 3.91B | ||
| 31.1x | 5.92x | 16.92x | - | 3.62B | ||
| -135.16x | - | - | -.--% | 2.51B | ||
| Average | 4.56x | 4.48x | 15.99x | 1.31% | 52.73B | |
| Weighted average by Cap. | 26.88x | 4.95x | 19.80x | 2.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- AB Stock
- A8D Stock
- Valuation AB Science
Select your edition
All financial news and data tailored to specific country editions
















